| Pembrolizumab in patients with extensive-stage small-cell lung cancer: results from the phase Ib KEYNOTE-028 study PA Ott, E Elez, S Hiret, DW Kim, A Morosky, S Saraf, B Piperdi, ... Journal of Clinical Oncology 35 (34), 3823-3829, 2017 | 549 | 2017 |
| Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial EW Alley, J Lopez, A Santoro, A Morosky, S Saraf, B Piperdi, ... The Lancet Oncology 18 (5), 623-630, 2017 | 525 | 2017 |
| Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1–positive endometrial cancer: results from the KEYNOTE-028 study PA Ott, YJ Bang, D Berton-Rigaud, E Elez, MJ Pishvaian, HS Rugo, ... Journal of Clinical Oncology 35 (22), 2535-2541, 2017 | 479 | 2017 |
| Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1–positive cervical cancer: results from the phase Ib KEYNOTE-028 trial JS Frenel, C Le Tourneau, B O’Neil, PA Ott, SA Piha-Paul, C Gomez-Roca, ... Journal of Clinical Oncology 35 (36), 4035-4041, 2017 | 473 | 2017 |
| Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1–positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study C Hsu, SH Lee, S Ejadi, C Even, RB Cohen, C Le Tourneau, JM Mehnert, ... Journal of Clinical Oncology 35 (36), 4050-4056, 2017 | 434 | 2017 |
| Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study ER Plimack, J Bellmunt, S Gupta, R Berger, LQM Chow, J Juco, ... The Lancet Oncology 18 (2), 212-220, 2017 | 369 | 2017 |
| Safety and antitumor activity of pembrolizumab in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer HS Rugo, JP Delord, SA Im, PA Ott, SA Piha-Paul, PL Bedard, J Sachdev, ... Clinical Cancer Research 24 (12), 2804-2811, 2018 | 327 | 2018 |
| Safety and antitumor activity of the anti–programmed death-1 antibody pembrolizumab in patients with advanced esophageal carcinoma T Doi, SA Piha-Paul, SI Jalal, S Saraf, J Lunceford, M Koshiji, J Bennouna Journal of Clinical Oncology 36 (1), 61-67, 2018 | 304 | 2018 |
| Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma BH O’Neil, JM Wallmark, D Lorente, E Elez, J Raimbourg, C Gomez-Roca, ... PloS one 12 (12), e0189848, 2017 | 272 | 2017 |
| Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal PA Ott, SA Piha-Paul, P Munster, MJ Pishvaian, EMJ Van Brummelen, ... Annals of Oncology 28 (5), 1036-1041, 2017 | 266 | 2017 |
| 24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed and carboplatin with or without Pembrolizumab as first-line therapy for advanced nonsquamous non–small cell lung … H Borghaei, CJ Langer, S Gadgeel, VA Papadimitrakopoulou, A Patnaik, ... Journal of Thoracic Oncology 14 (1), 124-129, 2019 | 261* | 2019 |
| Safety and antitumor activity of the anti–PD-1 antibody pembrolizumab in patients with advanced, PD-L1–positive papillary or follicular thyroid cancer JM Mehnert, A Varga, MS Brose, RR Aggarwal, CC Lin, A Prawira, ... BMC cancer 19, 1-9, 2019 | 183 | 2019 |
| Pembrolizumab for the treatment of advanced salivary gland carcinoma: findings of the phase 1b KEYNOTE-028 study RB Cohen, JP Delord, T Doi, SA Piha-Paul, SV Liu, J Gilbert, AP Algazi, ... American journal of clinical oncology 41 (11), 1083-1088, 2018 | 182 | 2018 |
| Pembrolizumab in combination with erlotinib or gefitinib as first-line therapy for advanced NSCLC with sensitizing EGFR mutation JCH Yang, SM Gadgeel, LVD Sequist, CL Wu, VA Papadimitrakopoulou, ... Journal of Thoracic Oncology 14 (3), 553-559, 2019 | 152 | 2019 |
| Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast … HS Rugo, JP Delord, SA Im, PA Ott, SA Piha-Paul, PL Bedard, J Sachdev, ... Cancer research 76 (4_Supplement), S5-07-S5-07, 2016 | 147 | 2016 |
| Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC MM Awad, SM Gadgeel, H Borghaei, A Patnaik, JCH Yang, SF Powell, ... Journal of Thoracic Oncology 16 (1), 162-168, 2021 | 131 | 2021 |
| Updated results for the advanced esophageal carcinoma cohort of the phase Ib KEYNOTE-028 study of pembrolizumab (MK-3475) T Doi, SA Piha-Paul, SI Jalal, H Mai-Dang, S Saraf, M Koshiji, I Csiki, ... J Clin Oncol 34 (4_suppl), 7, 2016 | 103 | 2016 |
| Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non–small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study SM Gadgeel, JP Stevenson, CJ Langer, L Gandhi, H Borghaei, A Patnaik, ... Lung Cancer 125, 273-281, 2018 | 87 | 2018 |
| Pembrolizumab in combination with ipilimumab as second-line or later therapy for advanced non–small-cell lung cancer: KEYNOTE-021 cohorts D and H MA Gubens, LV Sequist, JP Stevenson, SF Powell, LC Villaruz, ... Lung Cancer 130, 59-66, 2019 | 82 | 2019 |
| Pembrolizumab in patients with advanced cervical squamous cell cancer: Preliminary results from the phase Ib KEYNOTE-028 study. JS Frenel, C Le Tourneau, BH O'Neil, PA Ott, SA Piha-Paul, ... Journal of Clinical Oncology 34 (15_suppl), 5515-5515, 2016 | 64 | 2016 |
